|
|
Harry F. Hixson, Jr., Ph.D.
Director
 |
Harry F. Hixson, Jr., Ph.D., has served as a member of our Board of Directors since September 2004. Dr. Hixson serves as the interim Chief Executive Officer and the Chairman of the board of directors of Sequenom, Inc., a genomics company. Dr. Hixson served as Chief Executive Officer of BrainCells Inc., a neurogenesis-based drug discovery and development company, from July 2004 to September 2005, and as Chief Executive Officer of Elitra Pharmaceuticals, a biopharmaceutical company, from February 1998 to May 2003. Dr. Hixson held various management positions with Amgen, Inc., a biopharmaceutical company, from 1985 to 1991, most recently as President and Chief Operating Officer. Dr. Hixson also serves as a member of the board of directors of BrainCells Inc., Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company, and NovaBay Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Hixson holds a B.S. in Chemical Engineering from Purdue University, an M.B.A. from the University of Chicago and a Ph.D. in Physical Biochemistry from Purdue University. |
|
